GEN Share Price | Genomed SA Stock Analysis & Recommendation

Results Declared: Genomed SA has declared results on 13 Aug 2026! Click here to unlock the latest financial performance

Mojo Score Change: Genomed SA has changed its score on 13 Aug 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Genomed SA with Similar Stocks

Telemedycyna Polska SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 8.65%

The company has been able to generate a Return on Equity (avg) of 8.65% signifying low profitability per unit of shareholders funds

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.04

Poor long term growth as Net Sales has grown by an annual rate of 9.55% and Operating profit at 37.19% over the last 5 years

With ROE of 25.20%, it has a fair valuation with a 2.84 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 40 Million (Micro Cap)

P/E

11.00

Industry P/E

Dividend Yield

50.00%

Debt Equity

-0.45

Return on Equity

25.20%

Price to Book

3.25

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Jun 2026)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.62%

6 Months

-6.29%

1 Year

15.5%

2 Years

2.05%

3 Years

-19.89%

4 Years

-22.8%

5 Years

-30.7%

Genomed SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.55%

EBIT Growth (5y)

37.19%

EBIT to Interest (avg)

1.82

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

2.50

Tax Ratio

19.92%

Dividend Payout Ratio

58.30%

Pledged Shares

Institutional Holding

ROCE (avg)

32.79%

ROE (avg)

8.65%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.84

EV to EBIT

7.18

EV to EBITDA

6.00

EV to Capital Employed

4.37

EV to Sales

0.98

PEG Ratio

0.20

Dividend Yield

ROCE (Latest)

60.83%

ROE (Latest)

25.20%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 16.39% vs 17.31% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 400.00% vs 150.00% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.10",
          "val2": "6.10",
          "chgp": "16.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.90",
          "val2": "0.40",
          "chgp": "125.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.50",
          "val2": "0.10",
          "chgp": "400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "93.50%",
          "val2": "38.00%",
          "chgp": "5.55%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 26.52% vs 2.22% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 209.09% vs 22.22% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "29.10",
          "val2": "23.00",
          "chgp": "26.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.00",
          "val2": "2.10",
          "chgp": "138.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.40",
          "val2": "1.10",
          "chgp": "209.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "147.10%",
          "val2": "58.80%",
          "chgp": "8.83%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY

Jun'26

Jun'25

Change(%)

Net Sales

7.10

6.10

16.39%

Operating Profit (PBDIT) excl Other Income

0.90

0.40

125.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.50

0.10

400.00%

Operating Profit Margin (Excl OI)

93.50%

38.00%

5.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2026 is 16.39% vs 17.31% in Jun 2025

Consolidated Net Profit

YoY Growth in quarter ended Jun 2026 is 400.00% vs 150.00% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

29.10

23.00

26.52%

Operating Profit (PBDIT) excl Other Income

5.00

2.10

138.10%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

3.40

1.10

209.09%

Operating Profit Margin (Excl OI)

147.10%

58.80%

8.83%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 26.52% vs 2.22% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 209.09% vs 22.22% in Dec 2024

All Annual Results

Company CV

About Genomed SA

Genomed SA

Pharmaceuticals & Biotechnology

Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

Company Coordinates

Company Details

Ul. Ponczowa 12 , WARSZAWA None : 02-971

Tel: 48 22 6446019

http://www.genomed.pl

Registrar Details